Literature DB >> 2093052

Premonitory symptoms in migraine without aura: a clinical investigation.

G Santoro1, F Bernasconi, F Sessa, A Venco.   

Abstract

Thirty-three out of 100 patients affected by migraine without aura, reported premonitory symptoms in at least 50% of attacks and were considered to be affected by complete or premonitory common migraine. This group had a greater positive familiarity for migraine, a lower mean age of onset, and a higher average number of trigger factors compared with other patients. These three differences were statistically significant; hence we hypothesized that patients with migraine attacks generally preceded by premonitory symptoms have a stronger constitutional migraine trait with a premature weakening of their antinociceptive adaptation systems to the environment and to stressful events.

Entities:  

Mesh:

Year:  1990        PMID: 2093052

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  4 in total

1.  Dizziness and vertigo during the prodromal phase and headache phase of migraine: A systematic review and meta-analysis.

Authors:  Afrim Iljazi; Håkan Ashina; Richard B Lipton; Basit Chaudhry; Haidar M Al-Khazali; James G Naples; Henrik W Schytz; Vlasta Vukovic Cvetkovic; Rami Burstein; Sait Ashina
Journal:  Cephalalgia       Date:  2020-04-29       Impact factor: 6.292

Review 2.  The Enigma of Prodromes in Hereditary Angioedema (HAE).

Authors:  Iris Leibovich-Nassi; Avner Reshef
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-03       Impact factor: 8.667

3.  To what extent are patients with migraine able to predict attacks?

Authors:  Ana B Gago-Veiga; Josué Pagán; Kevin Henares; Patricia Heredia; Nuria González-García; María-Irene De Orbe; Jose L Ayala; Mónica Sobrado; Jose Vivancos
Journal:  J Pain Res       Date:  2018-09-27       Impact factor: 3.133

4.  Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.

Authors:  Messoud Ashina; Peter McAllister; Roger Cady; Joe Hirman; Anders Ettrup
Journal:  Cephalalgia       Date:  2022-03-18       Impact factor: 6.075

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.